"After 3 years of developing Xdivane™, we are proud to announce that we have successfully scaled up the production process to sufficient scale to commercialize and initiate clinical studies. " says
Xdivane™ is a biosimilar candidate to Opdivo® (nivolumab), an immuno-oncology PD-1 inhibitor used in the treatment of various types of cancer. The development program for Xdivane™ is on track for approval and launch at the time of US patent expiration in 2029. Clinical material will be produced this year, and clinical trials could be initiated first half of 2025.
“We have reproduced what we did in-house at pilot scale in industrial scale with selected production partner and thus demonstrated scalability for our patented platform technology for antibodies produced in mammalian cells with which we get a lower production cost compared to alternative systems.," says
Xbrane has worked actively with the development of Xdivane™ for the past three years, and by the end of 2024 Xbrane will have invested approximately
Xbrane is now running an active out-licensing process for Xdivane™ with the ambition to conclude a partnership in the third quarter of 2024. Xdivane™ is considered to be one out of few nivolumab biosimilar candidates in development for
The market for PD-1/PD-L1 inhibitors was estimated to
*)Mordor Intelligence
**)Evaluate Pharma
© Modular Finance, source